Tuesday, October 8, 2024
HomeHealth ConditionsCancerAspirin may prevent cognitive problems in cancer patients

Aspirin may prevent cognitive problems in cancer patients

Many cancer patients find that they develop cognitive problems as they become ill. A new study found that aspirin could limit cognitive problems in mice with cancer.

Almost half of cancer patients with solid tumors develop cognitive problems, including problems with learning, concentration, and memory. Some of these problems can remain decades after successful cancer treatment. Doctors used to think that chemotherapy was causing these cognitive impairments, but we now know that they can start even before treatment.

A group of Australian researchers have been studying cognitive problems associated with cancer. They suspected that inflammation, caused by tumors, may be the cause. They tested if ordinary aspirin, an anti-inflammatory drug, could help. They recently published their results in the scientific journal PLOS One.

Cognitive problems in mice with breast cancer

The researchers injected breast cancer tumor cells into the mammary glands of female mice. The mice started to develop measurable breast tumors two weeks after the injection.

One important measure of cognitive abilities is the ability to remember new things. In this study, the mice were tested on their ability to recognize objects that they’d been shown previously. The memory of mice injected with tumor cells was compared to the memory of healthy mice that had been injected with water only.

Mice had impaired memory within a week of the tumor cell injections. This was even before large tumors had started to form in the mice. Injecting mice with the chemicals produced by tumor cells, and not the tumor cells themselves, also caused memory problems. Because of this, the researchers guessed that the chemicals being released by tumor cells were causing the problem, not the tumor itself.

Inflammation appears to be the cause of the cognitive problems in cancer

Tumors produce lots of pro-inflammatory substances, so it is possible that this tumor-related inflammation is actually causing the cognitive problems in the mice. To test this, the researchers added aspirin, a drug that decreases inflammation, to the mice’s drinking water. The mice would have consumed an amount of aspirin equivalent to 100 mg/day in humans. This is considered a low dose of aspirin.

The aspirin prevented the memory problems in mice that had been injected with tumor cells. The aspirin had no effect on tumor size.

The effects of aspirin on cognition may be different in humans

This study had some limitations. For example, the memory problems were most severe within a few days after injection of the tumor cells. The problems appeared to become less severe, and maybe even disappear, two weeks after the tumor cells were injected. This raises the question of whether or not these cognitive problems are really comparable to those seen in human patients, which can last much longer. Also, the researchers started feeding the mice aspirin 36 hours before they injected them with cancer cells. Obviously, treatment could not start before the cancer is detected in human patients.

Finally, the fact that it works in mice does not guarantee that it will work in human patients. Aspirin needs to be tested in clinical trials to ensure that it actually works in the oncology clinic and to make sure that it doesn’t cause problems when mixed with other cancer treatments.

Despite these limitations, low-dose aspirin is safe and inexpensive. This means that it would be relatively easy to introduce into cancer treatment programs if a clinical trial confirms that it is helpful.

Written by Bryan Hughes, PhD

Reference: Walker, A. K., Chang, A., Ziegler, A. I., Dhillon, H. M., Vardy, J. L., & Sloan, E. K. (2018). Low dose aspirin blocks breast cancer-induced cognitive impairment in mice. PLOS ONE, 13(12), e0208593.

Bryan Hughes PhD
Bryan Hughes PhD
Bryan completed his Ph.D. in biology at McGill University, where he studied metabolism and the mechanisms of aging. He then worked at the University of Alberta as a Postdoctoral Research Fellow, investigating the causes of heart disease. After publishing many articles in scientific journals, he welcomes the opportunity to share the latest research findings with the wide audience of the Medical News Bulletin.
RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest News and Articles

SUBSCRIBE TO OUR NEWSLETTERS

Stay Connected
10,288FansLike
820FollowersFollow
249FollowersFollow
2,787FollowersFollow

Article of the month

ANKTIVA Boosts BCG for Bladder Cancer

The FDA has approved the immunotherapy-boosting drug, ANKTIVA, to be used with the existing immunotherapy drug, Bacillus Calmette-Guerin (BCG). This new therapy is a...

Joke Of The Day

Doctor to the patient: Have you ever had chicken pox? Patient: No, but I have had chicken nuggets.

ADVERTISE WITH US

error: Content is read-only and copy-protected.